Details of the Drug

General Information of Drug (ID: DM8R3GM)

Drug Name
KDT-501
Synonyms Protein kinase inhibitor (inflammatory disorders), KinDex Therapeutics; Protein kinase inhibitor (metabolic disorders),KinDex Therapeutics
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Phase 2 [1]
Type-2 diabetes 5A11 Phase 2 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C21H33KO5
Canonical SMILES
CC(C)CCC1C(=O)C(=C(C1(C(=O)CCC(C)C)[O-])O)C(=O)CC(C)C.[K+]
InChI
1S/C21H33O5.K/c1-12(2)7-9-15-19(24)18(16(22)11-14(5)6)20(25)21(15,26)17(23)10-8-13(3)4;/h12-15,25H,7-11H2,1-6H3;/q-1;+1/t15-,21+;/m1./s1
InChIKey
OBRIOHODJVKWGS-WSZABJOTSA-N
Cross-matching ID
PubChem CID
71587993
CAS Number
1374228-86-0
TTD ID
D03NLV
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT02444910) Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)